about
Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.BioSAVE: display of scored annotation within a sequence context.A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver TransplantBudget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence.Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes.The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus.Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis.Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK.Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective.Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents.A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden.Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice.An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices.Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness EvaluationDevelopment of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in IrelandA cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UKA patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United KingdomImpact of Stigma on People Living with Chronic Hepatitis BLong-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
P50
Q30980615-726AA0FD-37E5-4B73-A698-5CBD7D1A4531Q33325704-00D212D5-85D4-45ED-B0DA-44120A168143Q34016943-F631E35B-0362-41C7-A029-84D4D3790BF9Q36182011-8F8C32D0-BA90-4472-B485-6D702F494502Q37682802-7001AEBD-5E4E-4077-A868-DFBC41BE4641Q37818351-93993373-4815-486A-91DB-8588B072D912Q38676861-D0C16784-22C1-4152-A27E-09454CF7384EQ38699290-828893D6-D64C-4BF6-B6E7-EAEA98BC6968Q38746225-F00BECC2-8C42-415F-A08C-2F555BC3C4EBQ38868046-D0B5812F-062F-48F2-A59A-CAFCF82BAAA2Q39321463-42DE4D33-AAC3-4CA5-B79F-C6D2D5654CF8Q39514706-476C325B-7C78-4680-8BF4-653864DB715EQ39517890-15A3931C-0AAF-4AA2-93E7-A199DF1C6806Q39571328-FE40FC53-C5FC-4A90-8CE4-73649A579F90Q39620628-F958DC6F-A3C2-48D3-B4D0-AED2ACD0FC67Q39641512-C993D63B-52D4-4740-B45A-50E3D14E01E6Q39798455-EDC11A28-8B66-4BC9-BD17-33F69BA75CF7Q39993176-BC2BA5A5-168C-4B8B-926F-3A576A4F2775Q40708136-0E4F2A8B-5D7D-4B12-B62B-47C16A4E7DA1Q40923585-2816C1DE-AB92-4207-BAAF-FC0323D318CEQ41405604-D80548DB-0582-4F30-B0CF-81ABABB763B4Q41952202-422C3194-97C0-4F55-A9E6-C4C2E9266124Q42791841-2797C73A-CC85-4B03-B19F-C122FADA99B0Q46529831-1E8A4F34-3736-4023-B9B0-96F6A744DA26Q46967505-61988889-3898-4271-A795-6AEF3BD3C5FFQ47369149-C19EF866-7E84-4AFA-BCF8-746AE7CA1034Q47793365-73A2841D-1284-4BB7-9676-10E13AF49759Q47927613-CC48579D-BB6C-4833-8330-B0766DD03569Q50554731-777A9971-B0A3-4561-B51A-F1E6457D0060Q51769735-DD2B215D-70D3-4EB9-8AE0-B77F9D8DBDCCQ52564727-EA4ED1D0-699B-4FE6-9FA4-0CF2656AF03DQ53331706-314794D6-5FA2-48B6-B717-4DA4CC60C7A4Q54959259-CCED615A-AF58-41F1-9712-150446E6B720Q55334228-23121FAE-2A22-449F-A0D7-EA9241566B50Q88017603-2564251F-D279-4FEB-A704-021949D542C3Q89587011-887B42A4-16F6-444A-95AB-32F3BA9FF615Q89751126-E09EC4F2-EA4B-4FEA-AD18-54E460AB072AQ90621106-C01E4AD5-72F0-446C-A642-BAA95CE38AF5Q90669477-6AE7F1CD-9F58-4CCA-84E6-27AF733D9E1DQ91538572-D42246DE-46B0-44F4-9D3F-44FDA6005D30
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Richard F Pollock
@ast
Richard F Pollock
@en
Richard F Pollock
@es
Richard F Pollock
@nl
Richard F Pollock
@sl
type
label
Richard F Pollock
@ast
Richard F Pollock
@en
Richard F Pollock
@es
Richard F Pollock
@nl
Richard F Pollock
@sl
prefLabel
Richard F Pollock
@ast
Richard F Pollock
@en
Richard F Pollock
@es
Richard F Pollock
@nl
Richard F Pollock
@sl
P106
P21
P31
P496
0000-0002-9873-7507